Classifications: ergot alkaloid; dopamine agonist; Therapeutic: ergot alkaloid; antiparkinson agent
Pregnancy Category: B
0.5 mg tablets
Cabergoline is a synthetic ergot derivative, long-acting dopamine receptor agonist with a high affinity for D2 receptors in the anterior pituitary, suppresses prolactin secretion.
Cabergoline inhibits both puerperal lactation and pathologic hyperprolactinemia.
Treatment of hyperprolactinemia (idiopathic or secondary to pituitary adenomas).
Treatment of Parkinson's disease.
Uncontrolled hypertension and hypersensitivity to ergot derivatives; pregnancy-induced hypertension, preeclampsia, eclampsia,
Hepatic function impairment; elderly, psychosis; pregnancy (category B). Safety and efficacy in pediatric patients are unknown.
Route & Dosage
Adult: PO Start with 0.25 mg 2 times/wk, may increase by 0.25 mg 2 times/wk to a max of 1 mg 2 times/wk
Adult: PO Start with 0.5 mg q.d., may increase up to 2.5 mg q.d. (max: 5 mg/d)
- Give on same days each week.
Adverse Effects (≥1%)Body as a Whole:
, hot flashes. CV:
Postural hypotension. GI: Nausea, constipation,
abdominal pain, dyspepsia, vomiting, dry mouth, diarrhea
, flatulence. Endocrine:
Breast pain, dysmenorrhea. CNS: Headache, dizziness, paresthesia
, somnolence, depression
Concurrent use with phenothiazines
, and metoclopramide
decreases therapeutic effects of both drugs.
Rapidly absorbed GI tract, undergoes first-pass metabolism
23 h. Distribution:
4042% protein bound. Crosses placenta. Metabolism:
Extensively metabolized. Elimination:
Approximately 22% in urine, 60% in feces. Half-Life:
Assessment & Drug Effects
- Lab tests: Monitor serum prolactin levels to assess response to each dosing level.
- Monitor for hypotension, especially when given with other drugs known to lower BP.
Patient & Family Education
- Discontinue this drug once physician advises that serum prolactin level has been maintained for 6 mo.